Lenvaxen (Lenvatinib Mesylate INN equivalent to Lenvatinib) 10 mg

£0.00

Lenvaxen, containing Lenvatinib Mesylate, which is the International Nonproprietary Name (INN) equivalent to Lenvatinib, is a medication used for treating various cancers like thyroid, kidney, and liver cancers. Acting as a multi-targeted tyrosine kinase inhibitor, Lenvaxen hampers proteins involved in tumor growth and angiogenesis, thus impeding cancer progression. The usual dose is 10 mg once daily orally, with or without food, adjusted as per individual patient needs and tolerance. Common side effects might include high blood pressure, tiredness, diarrhea, and reduced appetite, whereas more serious effects such as liver problems and bleeding may occur. Regular monitoring is vital during Lenvaxen treatment to manage potential risks and ensure optimal treatment outcomes.

Add to wishlist
Share

    Indications: Lenvatinib is prescribed for two types of cancers:

    • Differentiated thyroid cancer (DTC) that has recurred locally or spread to other parts of the body, and is progressive despite previous radioactive iodine treatment.
    • Advanced renal cell carcinoma (RCC) following ineffective response to one prior anti-angiogenic therapy.

    Pharmacology: Lenvatinib Mesylate is a multikinase inhibitor that hampers the activities of various receptors involved in blood vessel formation and tumor growth, ultimately leading to tumor cell death.

    Dosage and Administration: The recommended starting dose is 24 mg orally once a day until disease progression or unacceptable adverse reactions. Dosage adjustments may be necessary based on individual patient factors and tolerability.

    Interactions: Lenvatinib may interact with various medications, particularly strong CYP3A4 inhibitors/inducers and drugs affecting stomach acidity. Patients should disclose all medications to their healthcare providers.

    Side Effects: Common side effects include high blood pressure, fatigue, diarrhea, reduced appetite, weight loss, protein in urine, and mouth sores. Serious side effects may comprise liver damage, bleeding events, and heart problems.

    Precautions and Warnings: Lenvatinib may induce high blood pressure, protein in urine, and heart issues. Patients should undergo regular monitoring for these conditions, along with liver function tests due to potential liver toxicity.

    Overdose Effects: If overdose occurs, supportive measures should be administered as there’s no specific antidote. Treatment focuses on managing symptoms.

    Product Name

    Lenvaxen

    Generic Name

    Lenvatinib Mesylate INN equivalent to Lenvatinib

    Formulation

    Capsule

    Available Pack size

    30 Capsules

    Strengths

    10 mg

    Reviews

    There are no reviews yet.

    Be the first to review “Lenvaxen (Lenvatinib Mesylate INN equivalent to Lenvatinib) 10 mg”